These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 7932417

  • 1. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus.
    Drenkard C, Villa AR, Alarcón-Segovia D, Pérez-Vázquez ME.
    J Rheumatol; 1994 Jun; 21(6):1067-72. PubMed ID: 7932417
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR.
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [Abstract] [Full Text] [Related]

  • 4. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM.
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [Abstract] [Full Text] [Related]

  • 5. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE.
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [Abstract] [Full Text] [Related]

  • 6. Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus.
    Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J, Alarcón-Segovia D.
    J Rheumatol; 1993 Mar; 20(3):437-42. PubMed ID: 8478848
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.
    Ward MM, Pyun E, Studenski S.
    Arch Intern Med; 1996 Jun 24; 156(12):1337-44. PubMed ID: 8651844
    [Abstract] [Full Text] [Related]

  • 9. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
    von Scheven E, Glidden DV, Elder ME.
    Arthritis Rheum; 2002 Aug 24; 47(4):414-20. PubMed ID: 12209489
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Retinal vascular lesions in systemic lupus erythematosus and secondary antiphospholipid syndrome].
    Ermakova NA, Alekberova ZS, Reshetniak TM, Kalashnikova LA, Kosheleva NM.
    Vestn Oftalmol; 2005 Aug 24; 121(5):31-6. PubMed ID: 16274063
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.